Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
BioNTech SE ADR falls Wednesday, underperforms market
The BioNTech SE ADR BNTX slipped 7.29% to $115.62 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.29% to 5,618.26 and Dow Jones Industrial Average DJIA falling 0.
UBS Keeps Their Hold Rating on BioNTech SE (BNTX)
UBS analyst Eliana Merle maintained a Hold rating on BioNTech SE (BNTX – Research Report) today and set a price target of $131.00. The
Jefferies Upgrades BioNTech SE - Depositary Receipt () (BNTX)
Fintel reports that on September 17, 2024, Jefferies upgraded their outlook for BioNTech SE - Depositary Receipt () (NasdaqGS:BNTX) from Hold to Buy. Analyst Price Forecast Suggests 8.06% Downside As of August 25,
BioNTech SE ADR rises Tuesday, outperforms market
The BioNTech SE ADR BNTX rallied 1.00% to $124.71 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.03% to 5,634.58 and the Dow Jones Industrial Average DJIA falling 0.
Zacks.com on MSN
8d
BioNTech (BNTX) Stock Jumps 5.8%: Will It Continue to Soar?
BioNTech (BNTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...
Morningstar
3d
BioNTech SE ADR BNTX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
4d
on MSN
BioNTech raised to buy at Jefferies on new cancer drug
BioNTech (NASDAQ:BNTX) shares traded higher on Tuesday after Jefferies upgraded the German COVID-19 vaccine maker to Buy from ...
1d
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...
Yahoo Finance
4d
BNTX Oct 2024 97.500 call (BNTX241018C00097500)
As of 16 September at 09:30 GMT-4. Market open. Adjusted closing price adjusted for splits and dividend and/or capital gain distributions.
4d
Decoding BioNTech's Options Activity: What's the Big Picture?
Today, Benzinga 's options scanner spotted 26 uncommon options trades for BioNTech. This isn't normal. The overall sentiment ...
5d
Buy Rating Affirmed for BioNTech SE Following Promising Clinical Trial Results in Oncology
H.C. Wainwright analyst Robert Burns has reiterated their bullish stance on BNTX stock, giving a Buy rating on September 9. Robert Burns has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback